about
Structure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive reviewA ranking method for the concurrent learning of compounds with various activity profiles.A network-based multi-target computational estimation scheme for anticoagulant activities of compoundsPrediction of chemical-protein interactions network with weighted network-based inference methodEffects of protein interaction data integration, representation and reliability on the use of network properties for drug target prediction.What is next for small-molecule drug discovery?A global view of drug-therapy interactionsA multi-target therapeutic potential of Prunus domestica gum stabilized nanoparticles exhibited prospective anticancer, antibacterial, urease-inhibition, anti-inflammatory and analgesic properties.Synthesis, biology and clinical significance of pentacyclic triterpenes: a multi-target approach to prevention and treatment of metabolic and vascular diseases.The relationship between the hierarchical position of proteins in the human signal transduction network and their rate of evolution.SignaLink 2 - a signaling pathway resource with multi-layered regulatory networksHomopharma: a new concept for exploring the molecular binding mechanisms and drug repurposing.Application of GQSAR for Scaffold Hopping and Lead Optimization in Multitarget Inhibitors.Evolutionary rate and duplicability in the Arabidopsis thaliana protein-protein interaction network.Finding multiple target optimal intervention in disease-related molecular network.Network strategies to understand the aging process and help age-related drug design.Study of the Hypoglycemic Activity of Derivatives of Isoflavones from Cicer arietinum L.Implications of endoplasmic reticulum stress, the unfolded protein response and apoptosis for molecular cancer therapy. Part II: targeting cell cycle events, caspases, NF-κB and the proteasome.Integration of phytochemicals and phytotherapy into cancer precision medicine.Weak-binding molecules are not drugs?-toward a systematic strategy for finding effective weak-binding drugs.Systemic QSAR and phenotypic virtual screening: chasing butterflies in drug discovery.Detecting similar binding pockets to enable systems polypharmacology.An Integrative Thrombosis Network: Visualization and Topological Analysis.Controlling Directed Protein Interaction Networks in Cancer.Antidiabetic effect of Dodonaea viscosa aerial parts in high fat diet and low dose streptozotocin-induced type 2 diabetic rats: a mechanistic approach.A Systematic Review of Computational Drug Discovery, Development, and Repurposing for Ebola Virus Disease Treatment.Rational design of multitargeted tyrosine kinase inhibitors: a novel approach.The MFHR1 Fusion Protein Is a Novel Synthetic Multitarget Complement Inhibitor with Therapeutic Potential.A computationally driven analysis of the polyphenol-protein interactome.Current trends in small molecule discovery targeting key cellular signaling events towards the combined management of diabetes and obesity.A desirability-based multi objective approach for the virtual screening discovery of broad-spectrum anti-gastric cancer agents.System-level multi-target drug discovery from natural products with applications to cardiovascular diseases.
P2860
Q27008867-C5ED0A99-5E50-4666-A02B-4EB9CECC2288Q27902271-43371F7A-43DB-4522-86AB-A6F5698E7883Q28477458-DC94DE86-7FBF-4850-A732-66DF351B8B29Q28481329-BBDCF4D6-D495-404C-BCDA-D08F2D7959B7Q30577213-96EFC51B-9237-4EE5-8C08-CD120E2A5F34Q31004268-52C9BAB1-B69D-4F05-AC03-CDB8FABE7D81Q33322388-89C507AC-6E97-4F37-B730-6E919409BCF6Q33722754-28892CDE-14AD-4687-A36A-27031133DC37Q34162283-3D2F5F9B-4579-48F6-AEC3-AC741EA0FEFCQ34423802-67E1FF40-C08C-4D14-BB47-A9DC625D1124Q34554087-F8BB2D4C-AB05-48F0-8FA2-F7D84A3C64A8Q34913200-C93430E5-E5D6-436D-9631-AB3CF24C3A32Q36091289-DAAE66F2-4A43-4A7E-9015-2AA289D45D67Q36524999-67AF4383-DFE2-4196-8DF8-B9D1B514CAF3Q37170511-4A6513F2-3385-4972-8C48-C9EBC0C2261DQ37402658-2FDD7791-A751-4FE5-94E2-5453DA47525DQ37736412-431C56BE-5CAE-49D0-B233-8DD8DFF196FDQ38088360-08961113-BAE0-4C25-82B7-658AA745583DQ38780465-02E72425-DF4C-46CA-BDCB-73D7ABA0E848Q38897226-6C74E977-E534-4D51-AAFD-8F6B2185028DQ39169235-C0D0938A-76FB-49AE-AA1F-9657C303F86DQ41002933-DCED260E-E01C-465E-9747-1FDFD1715606Q41444600-0858F9F5-D164-4DC7-BEA5-4D9F1A6D13E7Q41605713-BB12692D-7CBE-4279-A373-3FD6F80BCCB9Q42918183-9970218D-D673-4E87-B033-A277F8860E02Q44105963-4F9919AC-BAA0-4081-B3C8-376CE474A16AQ46086222-AA3BF090-BE6D-4BEE-BE81-0965C4ED1B76Q48241051-AB9E4B66-C4BC-4E1D-B46D-502A82689B5FQ49357556-25C44AAE-8563-4B9E-BE84-57EF233BE9C7Q49594358-546546BA-A581-45E1-AAB0-AB38D1BE288DQ50114279-8A9D414C-AA1E-4D33-BC6C-77C5240B2534Q51738057-583A8769-4474-467A-B126-5E94F9A6DAAA
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
How to design multi-target drugs.
@en
type
label
How to design multi-target drugs.
@en
prefLabel
How to design multi-target drugs.
@en
P2093
P2860
P356
P1476
How to design multi-target drugs
@en
P2093
Csaba Böde
Máté S Szalay
Péter Csermely
Tamás Korcsmáros
P2860
P304
P356
10.1517/17460441.2.6.799
P407
P577
2007-06-01T00:00:00Z